Oxford BioMedica (LSE:OXB) FFO


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.33
GF Value £5.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica FFO?

FFO (Funds from operations) only applies to REITs.

LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.33 is trading 18.1% above its estimated GF Value™ of £5.36. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • FFO:
  • GF Value™: £5.36 vs. price of £6.33 (18.1% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.33
Price
£5.36
GF Value